Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 1;162(10):bqab145.
doi: 10.1210/endocr/bqab145.

Does FFAR4 Agonism have Therapeutic Potential in Cardiometabolic Disease?

Abigail C Lay  1
Affiliations
Comment

Does FFAR4 Agonism have Therapeutic Potential in Cardiometabolic Disease?

Abigail C Lay. Endocrinology. .
No abstract available

Keywords: CVD; FFAR4; GPR120; atherosclerosis; cardiometabolic disease; diabetes; metabolic syndrome; obesity; vascular disease.

PubMed Disclaimer

Comment on

References

    1. Hilgendorf KI, Johnson CT, Mezger A, et al. Omega-3 fatty acids activate ciliary FFAR4 to control adipogenesis. Cell. 2019; 179(6):1289-1305.e1221. - PMC - PubMed
    1. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005;11(1):90-94. - PubMed
    1. Stuttgen GM, Sahoo D. FFAR4: a new player in cardiometabolic disease? Endocrinology. 2021;162(8):bqab111. - PMC - PubMed
    1. Oh DY, Walenta E, Akiyama TE, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. 2014;20(8):942-947. - PMC - PubMed
    1. Murphy KA, Harsch BA, Healy CL, et al. Free fatty acid receptor 4 responds to endogenous fatty acids to protect the heart from pressure overload. Cardiovasc Res. Published online March 22, 2021. doi: 10.1093/cvr/cvab111. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances